← Leaderboards
Jeffrey Breit
Pulmokine, Inc.
$1,136,252
Attributed
$2,272,504
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–15$2M$1.5M$1M$500K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$2,272,504 · 1
By mechanism
R44$2,272,504 · 1
Top collaborators
- Lawrence S. Zisman3 shared
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectAgonistAnimal ModelBaseBlood PressureBreathingCanis FamiliarisCardiopulmonaryCell ProliferationCharacteristicsClinical TrialsDesignDoseDrug FormulationsDrug KineticsEffective TherapyExcipientsFundingHalf-LifeHemodynamicsImatinibInhalation TherapyInhalatorsAdverse Effects
Grant awards (3)
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$5,000
R44 · FY2015 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$701,052
R44 · FY2013 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$1,566,452
R44 · FY2012 · HL